Acorda Therapeutics (NASDAQ:ACOR) Earns Hold Rating From Analysts at StockNews.com
Acorda Therapeutics (NASDAQ:ACOR) Earns Hold Rating From Analysts at StockNews.com
StockNews.com began coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a research note released on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company's stock.
斯托克新聞網在週六上午發佈的一份研究報告中開始報道阿科達治療公司(納斯達克:ACOR-GET Rating)的股票。該經紀公司對這家生物製藥公司的股票發佈了持有評級。
Acorda Therapeutics Stock Performance
Acorda Treateutics股票表現
Shares of NASDAQ ACOR opened at $0.40 on Friday. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.49 and a current ratio of 1.86. The firm has a market cap of $5.31 million, a price-to-earnings ratio of -0.05 and a beta of 0.45. The business's 50-day simple moving average is $0.44 and its 200-day simple moving average is $0.89. Acorda Therapeutics has a 52 week low of $0.28 and a 52 week high of $4.99.
上週五,納斯達克Acor的股價開盤報0.4美元。該公司的負債權益比率為2.10,速動比率為1.49,流動比率為1.86。該公司的市值為531萬美元,市盈率為-0.05倍,貝塔係數為0.45。該業務的50日簡單移動均線切入位在0.44美元,200日簡單移動均線切入位在0.89美元。Acorda Treateutics的52周低點為0.28美元,52周高點為4.99美元。
Institutional Trading of Acorda Therapeutics
Acorda Treateutics的機構交易
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Prudential Financial Inc. bought a new stake in shares of Acorda Therapeutics in the 2nd quarter worth approximately $28,000. Virtu Financial LLC bought a new position in shares of Acorda Therapeutics during the 2nd quarter worth approximately $68,000. Millennium Management LLC lifted its position in shares of Acorda Therapeutics by 661.2% during the 2nd quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company's stock worth $145,000 after buying an additional 270,588 shares during the period. Acadian Asset Management LLC lifted its position in shares of Acorda Therapeutics by 22.3% during the 4th quarter. Acadian Asset Management LLC now owns 467,739 shares of the biopharmaceutical company's stock worth $1,116,000 after buying an additional 85,335 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Acorda Therapeutics by 27.4% during the 2nd quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company's stock worth $420,000 after buying an additional 194,100 shares during the period. Institutional investors and hedge funds own 50.24% of the company's stock.
一些對衝基金和其他機構投資者最近增持或減持了該業務的股份。保誠金融公司在第二季度購買了價值約28,000美元的Acorda Treateutics新股。Virtu Financial LLC在第二季度購買了價值約6.8萬美元的Acorda治療公司的新股票頭寸。千禧管理有限責任公司在第二季度將其在阿科達治療公司的股票頭寸提高了661.2%。Millennium Management LLC現在持有這家生物製藥公司311,509股股票,價值145,000美元,在此期間又購買了270,588股。Acadian Asset Management LLC在第四季度將其在Acorda Treateutics的股票頭寸提高了22.3%。Acadian Asset Management LLC現在擁有這家生物製藥公司467,739股股票,價值111.6萬美元,在此期間又購買了85,335股。最後,復興技術有限責任公司在第二季度將其在Acorda治療公司的股票頭寸提高了27.4%。復興科技有限責任公司現在持有這家生物製藥公司價值42萬美元的901,318股股票,在此期間又購買了194,100股。機構投資者和對衝基金持有該公司50.24%的股票。
About Acorda Therapeutics
關於阿科達治療公司
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Acorda治療公司是一家生物製藥公司,在美國開發和銷售神經疾病的治療方法。該公司在歐洲營銷Ampyra(達法普利定),一種改善多發性硬化症(MS)患者行走能力的口服藥物;以及Inbrija,用於治療帕金森病的間歇期。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- Is Five Below Trying to Punch Too High?
- These 3 Reports Will Tell Us Much About the Current Economy
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 免費獲取StockNews.com關於Acorda治療公司(ACOR)的研究報告
- 下面的五個是不是打得太高了?
- 這三份報告將告訴我們許多關於當前經濟的情況。
- 這就是現在對標準普爾500指數的預期
- 關於甲骨文的FQ1報告,你需要知道的兩件事
- 波動市場的三隻價值股
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Acorda治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Acorda Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。